Evidence map›Paper›PMID 21069290›Full record

Trial reportIntensive care medicine2011

Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease.

Alain Fraisse, Ghazwan Butrous, Mary B Taylor, Michael Oakes, Maria Dilleen, David L Wessel

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Intensive care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2016
    Guideline
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Development of nanotechnology in andrology.Translational andrology and urology · 2020
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Safety of sildenafil in infants*.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2014
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Current challenges in pediatric pulmonary hypertension.Seminars in respiratory and critical care medicine · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Alain FraisseCardiologie Pédiatrique, Pôle de Pédiatrie, Hôpital de la Timone, Marseille Cedex 05, France.
Ghazwan Butrous
Mary B Taylor
Michael Oakes
Maria Dilleen
David L Wessel
Pfizer (United Kingdom) · GBChildren's National · USHôpital de la Timone · FRMonroe Carell Jr. Children's Hospital · USUniversity of Kent · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of intravenous sildenafil for immediate postoperative pulmonary hypertension (PH) in pediatric patients undergoing congenital heart surgery.

methodsA double-blind, multicenter, placebo-controlled, dose-ranging, parallel-group trial was conducted. Patients were randomized to one of three doses of intravenous sildenafil, or placebo, for a minimum of 24 h.

resultsThe study was heavily underpowered. Whereas enrollment of 228 patients (57 per treatment arm) was required to achieve the sample size estimate to detect difference between arms, the sponsor terminated the study after 15 months owing to slow patient accrual. Seventeen patients (median age 5 months) experiencing postoperative PH were randomized and treated, five with placebo and four each with low-, medium-, and high-dose sildenafil. In the first 24 h, 40% of placebo and 17% of sildenafil patients required additional therapy (p = 0.330). Median time to extubation (3 versus 8 days, p = 0.023) and intensive care unit stay (6 versus 15 days, p = 0.008) were shorter for sildenafil patients. Mean ± standard deviation systolic pulmonary artery pressure was reduced with sildenafil (46 ± 11 to 35 ± 6 mmHg, p = 0.027 versus placebo). No adverse events or systemic hypotension were attributed to sildenafil.

conclusionIntravenous sildenafil reduced pulmonary artery pressure and shortened time to extubation and intensive care unit stay in children with postoperative PH.

Indexed as

Heart Defects, CongenitalPostoperative ComplicationsAdolescentChildChild, PreschoolDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFemaleHumansHypertension, PulmonaryInfantInfusions, IntravenousMalePiperazinesPurinesSildenafil CitratePiperazinesPurinesSildenafil CitrateSulfonesVasodilator Agents

Identifiers

PMID21069290
PMCPMC3042092
OpenAlexW2152170583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.